E-Paper
‘Great New Year’s gift’: Covid task force chief explains decision to vaccinate children
The vaccination drive for those between 15-18 years of age will start from January 3, 2022, which was announced by PM Modi on December 25 amid rising Covid-19 cases linked to the Omicron variant of the coronavirus.
Prime Minister Narendra Modi’s decision to include adolescents between 15-18 years of age in the country’s vaccination drive against coronavirus disease (Covid-19) has several benefits, Dr NK Arora, chairperson of Covid-19 working group of the National Technical Advisory Group on Immunisation in India (NTAGI), has said.
Dr Arora has said the country already has a vaccine for children, Bharat Biotech’s Covaxin, which has shown it has a very good immune response in them in trials.
Arora’s comments come ahead of the vaccination drive for those between 15-18 years of age from January 3, 2022, which was announced by PM Modi on December 25 amid rising Covid-19 cases linked to the Omicron variant of the coronavirus.
Also read | Vaccination for 15-18 years: Only Covaxin likely to be administered
"Children between the age of 12 and 18 years, particularly those in the age group of 15 to 18 years, are very much like adults. Our research within the country also says that almost two-thirds of the deaths which occurred due to Covid in India are within this age group. So, this decision was mainly taken to protect the adolescents,” Arora told ANI in an interview.
He also listed two other advantages of immunising adolescents against Covid-19.
“One is that they are quite mobile, they have to go to the school colleges and their risk of getting an infection, particularly in the light of Omicron, is present,” he explained.
Also read | Policy on booster, additional Covid-19 vaccine doses in 2 weeks: Dr NK Arora
"Secondly, many times these adolescents get infection into their households where elderly and those with comorbidities can get infected. So, in view of all this, the country has decided to introduce vaccination for children between 15 to 18 years," he said.
He also said immunisation of these children can be started in a short period without any specific preparation and that the dosage requirement will be the same as adults.
Dr Arora said Bharat Biotech's Covaxin has shown a “very good” immune response during trials.
Also read | 9-12 months' gap likely between 2nd dose and 'booster' precaution dose: Reports
"In fact, it is slightly better than adults. Secondly, this vaccine is a safe vaccine, and even local effects like pain, swelling in the arms is much less as compared to adults. We would like to offer this protection to our adolescents," he said.
"Although the disease's effects are much milder, but as we know many schools have opened. A lot of parents are still not very confident in sending their children to schools,” he added.
“So this vaccination drive will also be giving confidence to them. I would say it's a great New Year gift for our adolescents."
